Abstract: The invention relates to a veterinary composition for intramammary administration comprising a combination of an antibacterial agent and a Toll-Like-Receptor (TLR) agonist and to the use of said composition for the treatment of mastitis in lactating ruminants.

Abstract: A radiotherapy system includes a radiotherapy device, such as a LINAC, operable to direct a radiation beam from a head thereof during operation, a field detector positioned to be within the radiation beam during operation of the radiotherapy device and operable to generate a beam measurement signal, a reference detector positioned to be outside of the radiation beam during operation of the radiotherapy device and operable to generate a reference signal, and at least one computer in signal communication with the field detector and the reference detector and configured with software to normalize the beam measurement signal based on the reference signal and to output a normalized beam measurement.

Abstract: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

Abstract: A process is disclosed for the production of cyclic di-guanosine monophosphate (c-di-GMP) without the use of protecting groups by means of an enzymatic synthesis. The process comprises the coupling of two guanosine triphosphate (GTP) molecules so as to form a c-di-GMP molecule. This is done under the influence of a mutant diguanylate cyclase (DGC) comprising the amino acid sequence V153M154G155G156. It has been found that the DGC is obtainable from inclusion bodies, and therewith can be made available in amounts sufficient to improve the c-di-GMP synthesis. Particularly, the latter synthesis can be conducted in a one-pot method starting from commercially available bulk chemicals and allows upscaling to a commercial production scale.

Abstract: Embodiments of the present invention include a drainage channel comprising a first barrier for containment and a second barrier for containment. In one embodiment, the second barrier comprises a liner and a support. In a further embodiment, the support substantially secures at least a portion of the second barrier in the first barrier.

Abstract: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

Abstract: Methods of providing a rear perspective viewing for a consumer in a retail clothing store include: a) providing an image system; b) providing a receiver, wherein the image system collects an actual image of a person and transmits the image to the receiver, c) providing at least one monitor, wherein at least one of the at least one monitor is located at least 90 degrees from the image system and wherein the at least one monitor receives the actual image from the receiver; and d) providing a retail clothing space comprising the image system and the at least one monitor.

Abstract: The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or a pharmaceutically acceptable salt of any of the aforementioned, in combination with a pharmaceutically acceptable carrier. The invention also encompasses a method for treating a cyclooxygenase-2 mediated disease or condition in a human patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising administering to the patient this pharmaceutical composition.

Abstract: A system includes a first bus coupler element, a second bus coupler element, and a visual element associated with the second bus coupler element and including a transparent media enabling the second coupler element to be visually aligned with the first coupler element.

Abstract: A controller sends signals to an electromagnetic coupler associated with a bus. The signals are arranged to set a coupling strength of the coupler.

Abstract: A bendable portion, which is arranged at the distal end of an insertion tube of an endoscope, comprises a plurality of tube segments, each of said tube segments having connecting means that cooperate with the connecting means of the adjacent tube segment, as well as control wires that can control the bending of the bendable portion. The respective connecting means of a tube segment are provided such that they axially protrude from the faces of the tube segment and are located within the mantle of the tube segment and such that they do not exceed the thickness of the mantle. The connecting means, which are provided on the respective faces of adjacent tube segments and which are located opposite each other, complement each other in the manner of a hinge-type connection.

Abstract: The present invention encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and nitric oxide releasing aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability.

Abstract: A system includes a first bus coupler element, a second bus coupler element, and a visual element associated with the second bus coupler element and including a transparent media enabling the second coupler element to be visually aligned with the first coupler element.

Abstract: A system and method for splicing reeled media using operational feedback. According to certain embodiments, the method of operating a media production system involves sensing speed parameters of first and second reeled media, tracking an unwinding parameter of the first reeled media, and positionally tracking a leading end position of the second reeled media. The method also involves controlling splicing between the first and second reeled media based at least partially on the speed parameters, the unwinding parameter, and the leading end position.

Abstract: Calibrating return time includes determining clock calibration information based on clock signals local to a master device and return clock signals corresponding to each of at least two slave devices, storing clock calibration information with respect to each of the slave devices with which the master device will communicate using a bus, and, after the clock calibration information has been stored, resynchronizing data signals that are received from each of the slave devices based on the corresponding stored clock calibration information.

Abstract: A method of monitoring an element of a plant is disclosed which comprises the steps of: (a) producing an image representing the state of the element and recording the image in the form of a data set; (b) comparing the data set with a norm in order to determine a change in the state of the element; and (c) producing a signal which represents the change in the state of the element.

Abstract: A method for preventing heartburn episodes in a patient susceptible to suffering heartburn episodes following ingestion of heartburn-inducing food or beverage, comprising administering to the patient, 30 minutes prior to consumption by the patient of the food or beverage, a composition comprising an amount of famotidine of 10 mg.

Abstract: A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.A method for treating a patient suffering from heartburn and having no substantial esophageal erosion, comprising administering to the patient a composition comprising an amount of famotidine between about 5 mg and 10 mg, and an antacid. In one embodiment, the amount of famotidine is about 5 mg. In another embodiment, the amount of famotidine is about 10 mg.

Abstract: Slide for the microscopic evaluation of liquid specimens comprising a base plate, at least one evaluation chamber and a cover foil. The evaluation chambers have a specimen application zone and an evaluation area. A capillary gap is located between the evaluation zone and the cover foil. An improved slide compared to known devices was achieved by using a foil to cover the evaluation chambers and by spacers which ensure a defined thickness of the capillary gap.

Abstract: A reagent supply system for a medical anlytical instrument includes a reagent space provided on the instrument and reagent vessels which are received in the reagent space. In the reagent space there is provided at least one reagent vessel compartment with a bottom, lateral guide elements, and a top guiding element, as well as a front stop. The instrument contains a fluid communication system for connection with a reagent vessel situated in the reagent vessel compartment. On the end face of the reagent vessel compartment is disposed a hollow needle near the bottom surface thereof and extending in a direction which is parallel to the bottom surface. The reagent vessel has on its front wall facing the end face a pierceable seal with a pierceable elastic stopper.